Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03836053 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03836053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
March 4, 2019
Completion date
April 21, 2022
Enrollment
23 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma